New evidence: Metformin unsuitable as routine adjuvant for breast cancer: A drugtarget mendelian randomization analysis

The potential efficacy of metformin in breast cancer (BC) has been hotly discussed but never conclusive. This genetics-based study aimed to evaluate the relationships between metformin targets and BC risk.